CliffBio
small molecule

VIJOICE

ALPELISIB

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIJOICE
Active ingredientALPELISIB
Strength200MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
12427141February 2037use U-4288
11433059February 2037use U-4359
8227462April 2033substance, product
8476268September 2029substance, product

Regulatory exclusivity

CodeExpires
ODE-396April 2029

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIJOICE patent cliff — loss of exclusivity February 2037 | CliffBio